S Smeland
Overview
Explore the profile of S Smeland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whelan J, Bielack S, Marina N, Smeland S, Jovic G, Hook J, et al.
Ann Oncol
. 2014 Nov;
26(2):407-14.
PMID: 25421877
Background: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on...
2.
Luksch R, Tienghi A, Hall K, Fagioli F, Picci P, Barbieri E, et al.
Ann Oncol
. 2012 Jul;
23(11):2970-2976.
PMID: 22771824
Background: The Italian Sarcoma Group and the Scandinavian Sarcoma Group designed a joint study to improve the prognosis for patients with Ewing's family tumors and synchronous metastatic disease limited to...
3.
Bjerkehagen B, Smastuen M, Hall K, Skjeldal S, Smeland S, Fossa S
Br J Cancer
. 2011 Dec;
106(2):297-306.
PMID: 22173669
Background: This study aims to provide reasons for the poor sarcoma-related survival in patients with radiation-induced sarcoma (RIS). Methods: We performed a case-control study comparing sarcoma-related survival of 98 patients...
4.
Ferrari S, Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, et al.
Ann Oncol
. 2010 Nov;
22(5):1221-1227.
PMID: 21059639
Background: High-dose chemotherapy (HDT) was added to conventional chemotherapy in Ewing sarcoma family tumor (EFT) patients, poor responders (PRs) to induction chemotherapy in order to improve their survival. Patients And...
5.
Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes M, et al.
Cancer Treat Res
. 2010 Mar;
152:339-53.
PMID: 20213400
The introduction of multi-agent chemotherapy dramatically improved the outcome for patients with osteosarcoma. However, we appear to have reached a plateau in outcome with a long-term event-free survival of 60-70%....
6.
Storlazzi C, Brekke H, Mandahl N, Brosjo O, Smeland S, Lothe R, et al.
J Pathol
. 2006 May;
209(4):492-500.
PMID: 16721726
Previous studies have suggested that amplification of genes, notably the TOP2A gene, on chromosome arm 17q may be important for the development of malignant peripheral nerve sheath tumour (MPNST). In...
7.
Hagen E, Myhre A, Smeland S, Halvorsen B, Norum K, Blomhoff R
J Nutr Biochem
. 2004 Nov;
10(6):345-52.
PMID: 15539309
Vitamin A plays an important role in reducing infectious disease morbidity and mortality by enhancing immunity, an effect that is partly mediated by macrophages. Thus, knowing how these cells take...
8.
Smeland S, Blystad A, Kvaloy S, Ikonomou I, Delabie J, Kvalheim G, et al.
Ann Oncol
. 2004 Jun;
15(7):1072-8.
PMID: 15205201
Background: Burkitt's/Burkitt-like lymphoma (BL/BLL) are highly aggressive lymphomas mainly affecting children and young adults. We report the results in adolescent and adult patients with the use of three successive regimens....
9.
Smeland S, Wiebe T, Bohling T, Brosjo O, Jonsson K, Alvegard T
Acta Orthop Scand Suppl
. 2004 Jun;
75(311):92-8.
PMID: 15188671
No abstract available.
10.
Smeland S, Wiebe T, Brosjo O, Bohling T, Alvegard T
Acta Orthop Scand Suppl
. 2004 Jun;
75(311):87-91.
PMID: 15188670
No abstract available.